Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of Myocet plus carboplatin in advanced or recurrent endometrial cancer
2007-004060-40Phase 2Completed
- Sponsor
- AGO Austria
- Start
- Oct 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin and carboplatin in endometrial cancer (EC), sponsored by AGO Austria. Primary endpoint: Tumor response rate. Started Oct 2007; status: completed.
02
Drugs
doxorubicincarboplatin
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2007-004060-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004060-40.